We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals

855 hedge funds and large institutions have $58.3B invested in Vertex Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 136 funds opening new positions, 331 increasing their positions, 273 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more funds holding in top 10

Funds holding in top 10: 18 → 32 (+14)

58% more first-time investments, than exits

New positions opened: 136 | Existing positions closed: 86

21% more repeat investments, than reductions

Existing positions increased: 331 | Existing positions reduced: 273

16% more call options, than puts

Call options by funds: $306M | Put options by funds: $264M

5% more funds holding

Funds holding: 814 → 855 (+41)

8% more capital inflows, than outflows

Capital inflows: $3.29B | Capital outflows: $3.04B

0.4% less ownership

Funds ownership: 94.94% → 94.54% (-0.4%)

Holders
855
Holders Change
+41
Holders Change %
+5.04%
% of All Funds
18.79%
Holding in Top 10
32
Holding in Top 10 Change
+14
Holding in Top 10 Change %
+77.78%
% of All Funds
0.7%
New
136
Increased
331
Reduced
273
Closed
86
Calls
$306M
Puts
$264M
Net Calls
+$42.4M
Net Calls Change
+$61.7M

VRTX Hedge Fund Activity: Q1 2020 in Review

855 of the 4,550 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2020, worth a combined $58.3B — up 9.1% from $53.4B a quarter earlier.

Buyers outnumbered sellers: 136 funds opened new VRTX positions and 86 closed out — a net gain of 50 holders — while 331 added to existing stakes and 273 trimmed.

The largest buyer was Capital World Investors, adding an estimated $455M. The largest seller was T. Rowe Price Associates, cutting an estimated $666M.

  • 855 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2020, up from 814 in Q4 2019.
  • Funds reported $58.3B of Vertex Pharmaceuticals stock for Q1 2020, up 9.1% quarter-over-quarter.
  • 136 funds opened new Vertex Pharmaceuticals positions in Q1 2020 and 86 closed out, a net change of +50 holders.
  • The largest Vertex Pharmaceuticals buyer in Q1 2020 was Capital World Investors, an estimated $455M added.
  • The largest Vertex Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $666M sold.

Based on aggregated 13F filings for Q1 2020.